First Time Loading...
P

Panagene Inc
KOSDAQ:046210

Watchlist Manager
Panagene Inc
KOSDAQ:046210
Watchlist
Price: 4 070 KRW -0.25% Market Closed
Updated: May 3, 2024
Section:
 

Relative Value

The Relative Value of one Panagene Inc stock under the Base Case scenario is 1 655.38 KRW. Compared to the current market price of 4 070 KRW, Panagene Inc is Overvalued by 59%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
1 655.38 KRW
Overvaluation 59%
Relative Value
Price
P
Worst Case
Base Case
Best Case

Valuation Multiples

13.6
P/S
P/S
Price to Sales
13.6
vs History
14
vs Industry
41
Median 3Y
9.3
Median 5Y
10.1
Industry
8.1
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
1
Median 3Y
27.8
Median 5Y
27.2
Industry
26.2
More Details
4 619.4
P/OCF
P/OCF
Price to OCF
4 619.4
vs History
4
vs Industry
0
Median 3Y
33.1
Median 5Y
40.5
Industry
22.6
More Details
6.5
P/FCFE
P/FCFE
Price to FCFE
6.5
vs History
76
vs Industry
10
Median 3Y
30.7
Median 5Y
31.6
Industry
21.3
More Details
2.6
P/B
P/B
Price to Book Value
2.6
vs History
90
vs Industry
36
Median 3Y
3.9
Median 5Y
4.2
Industry
2.5
More Details
7.4
EV/S
EV/S
Enterprise Value to Sales
7.4
vs History
55
vs Industry
45
Median 3Y
7.5
Median 5Y
8.2
Industry
7.3
More Details
11
EV/GP
EV/GP
Enterprise Value to Gross Profit
11
vs History
57
vs Industry
38
Median 3Y
11
Median 5Y
12.1
Industry
9.1
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
1
Median 3Y
22.7
Median 5Y
22.7
Industry
4.4
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
0
Median 3Y
28.8
Median 5Y
25.9
Industry
4.3
More Details
2 494.6
EV/OCF
EV/OCF
Enterprise Value to OCF
2 494.6
vs History
4
vs Industry
0
Median 3Y
29.8
Median 5Y
34.7
Industry
5.4
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
2
Median 3Y
25.2
Median 5Y
26.7
Industry
3.2
More Details
6.6
EV/IC
EV/IC
Enterprise Value to IC
6.6
vs History
52
vs Industry
28
Median 3Y
7.1
Median 5Y
7.2
Industry
5
More Details

Multiples Across Competitors

Competitors Multiples
Panagene Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
KR
Panagene Inc
KOSDAQ:046210
166.9B KRW 13.6 -34.7 -107.2 -49
US
Abbvie Inc
NYSE:ABBV
284B USD 5.2 58.9 12.8 19.5
US
Amgen Inc
NASDAQ:AMGN
149.1B USD 5.3 22.2 16.5 24.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
103.1B USD 10.4 28.5 22.8 23.9
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
102.6B USD 7.8 25.9 17.4 19.1
AU
CSL Ltd
ASX:CSL
133B AUD 6.2 35.4 21.4 26.6
US
Gilead Sciences Inc
NASDAQ:GILD
81.4B USD 3 168.2 6.7 8.8
US
Moderna Inc
NASDAQ:MRNA
48B USD 7 -10.2 -11 -9.4
US
Seagen Inc
NASDAQ:SGEN
43.1B USD 18.8 -57.5 -61.9 -55.8
US
Biogen Inc
NASDAQ:BIIB
31.1B USD 3.2 26.6 13.7 17.1
KR
Celltrion Inc
KRX:068270
38.9T KRW 17.9 72.5 44.4 61.1
P/E Multiple
Earnings Growth
KR
P
Panagene Inc
KOSDAQ:046210
Average P/E: 54.8
Negative Multiple: -34.7 		N/A
US
Abbvie Inc
NYSE:ABBV
58.9
405%
US
Amgen Inc
NASDAQ:AMGN
22.2
82%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28.5
49%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
25.9
46%
AU
CSL Ltd
ASX:CSL
35.4
84%
US
Gilead Sciences Inc
NASDAQ:GILD
168.2
75%
US
Moderna Inc
NASDAQ:MRNA
Negative Multiple: -10.2 N/A
US
Seagen Inc
NASDAQ:SGEN
Negative Multiple: -57.5 N/A
US
Biogen Inc
NASDAQ:BIIB
26.6
154%
KR
Celltrion Inc
KRX:068270
72.5
105%
EV/EBITDA Multiple
EBITDA Growth
KR
P
Panagene Inc
KOSDAQ:046210
Average EV/EBITDA: 19.5
Negative Multiple: -107.2 		N/A
US
Abbvie Inc
NYSE:ABBV
12.8
26%
US
Amgen Inc
NASDAQ:AMGN
16.5
62%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.8
59%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.4
50%
AU
CSL Ltd
ASX:CSL
21.4
54%
US
Gilead Sciences Inc
NASDAQ:GILD
6.7
18%
US
Moderna Inc
NASDAQ:MRNA
Negative Multiple: -11 N/A
US
Seagen Inc
NASDAQ:SGEN
Negative Multiple: -61.9 N/A
US
Biogen Inc
NASDAQ:BIIB
13.7
67%
KR
Celltrion Inc
KRX:068270
44.4
109%
EV/EBIT Multiple
EBIT Growth
KR
P
Panagene Inc
KOSDAQ:046210
Average EV/EBIT: 25.1
Negative Multiple: -49 		N/A
US
Abbvie Inc
NYSE:ABBV
19.5
79%
US
Amgen Inc
NASDAQ:AMGN
24.7
98%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.9
61%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.1
50%
AU
CSL Ltd
ASX:CSL
26.6
70%
US
Gilead Sciences Inc
NASDAQ:GILD
8.8
35%
US
Moderna Inc
NASDAQ:MRNA
Negative Multiple: -9.4 N/A
US
Seagen Inc
NASDAQ:SGEN
Negative Multiple: -55.8 N/A
US
Biogen Inc
NASDAQ:BIIB
17.1
75%
KR
Celltrion Inc
KRX:068270
61.1
138%

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 133,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.